Pharma Mar, S.A. (BME:PHM)

Market Cap	1.45B +0.8%
Revenue (ttm)	218.64M +15.5%
Net Income	56.13M +33.6%
EPS	3.11 +29.1%
Shares Out	17.34M
PE Ratio	26.86
Forward PE	20.24
Dividend	1.00 (1.22%)
Ex-Dividend Date	Jul 8, 2026

Volume	29,225
Open	83.50
Previous Close	83.85
Day's Range	83.50 - 85.10
52-Week Range	64.00 - 105.20
Beta	0.43
Analysts	Buy
Price Target	104.39 (+24.87%)
Earnings Date	Jul 30, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 505
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Analyst Summary

According to 9 analysts, the average rating for PHM stock is "Buy." The 12-month stock price target is €104.39, which is an increase of 24.87% from the latest price.

Price Target

€104.39

(24.87% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error